Indeed, MGPT expanded the spectrum of actionable findings, i.e., in addition to BRCA PVs, it identified PVs in non-BRCA BC susceptibility genes in approximately 5% of cases, and PVs in CPS genes, either related or unrelated to the patient’s phenotype, in about 1% of patients. Here, CAD is linked to breast cancer.